poliomyelitis
Conditions
Interventions
Active safety monitoring:Non intervention
Passive security monitoring:Non intervention
Sponsors
Center for Disease Control and Prevention, Shanxi Provincial
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy infants and young children of 2 months old; 2. The subject's legal guardian signs the informed consent form and signs the date; 3. The subject's legal guardian can participate in all planned follow-ups (e.g. complete the diary card and return to participate in the visit); 4. Those who were judged to be healthy according to medical history, physical examination and clinical examination, and whose axillary body temperature was <= 37.0 degrees C.
Exclusion criteria
Exclusion criteria: 1. Have a history of poliomyelitis ; 2. People with a history of dystocia, suffocation rescue, neurological damage; 3. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; 4. Have a history of epilepsy, convulsions, or convulsions, or have a family history of mental illness; 5. Those who have received immune enhancement or inhibitor therapy within 3 months (continuous oral or instillation for more than 14 days); 6. Has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; 7. No spleen and spleen function defects caused by any situation; 8. Known or suspected diseases include: severe respiratory disease, severe cardiovascular disease, liver and kidney disease, skin disease, malignant tumor; in the acute attack of chronic disease; 9. A history of abnormal blood coagulation (such as coagulation factor deficiency, coagulopathy); 10. Have a history of severe allergic reactions to vaccination; 11. Those who are allergic to any component of the surveillance vaccine; 12. Have received live attenuated vaccine within 14 days; have received other vaccines within 7 days; 13. Are or plan to participate in other clinical trials in the near future; 14. The investigator judges other situations that are not suitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions / events;Incidence of adverse reactions / events;Incidence of severe adverse events (SAE); | — |
Countries
China
Contacts
Public ContactShaoying Chang
Shanxi Center for Disease Control and Prevention
Outcome results
None listed